Hepatopancreatobiliary Carcinoma — Research

Hepatopancreatobiliary Carcinoma — Research · CancerIndex

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

pubmedComputed3 windows · counts computed by CancerIndex from PubMed E-utilities; the exact query is stored with each count.

Window	Period	Records (count)	Exact query	Computed	Source
All time	… → 2026-09-11	91	`("Hepatopancreatobiliary Carcinoma"[tiab] OR "HPB Cancer"[tiab] OR "HPB Carcinoma"[tiab] OR "Hepatopancreatobiliary Cancer"[tiab])`	2026-09-11	pubmed
Last 5 years	2021-01-01 → 2026-12-31	76	`("Hepatopancreatobiliary Carcinoma"[tiab] OR "HPB Cancer"[tiab] OR "HPB Carcinoma"[tiab] OR "Hepatopancreatobiliary Cancer"[tiab]) AND (2021/01/01:2026/12/31[dp])`	2026-09-11	pubmed
Last 12 months	2025-09-11 → 2026-09-11	21	`("Hepatopancreatobiliary Carcinoma"[tiab] OR "HPB Cancer"[tiab] OR "HPB Carcinoma"[tiab] OR "Hepatopancreatobiliary Cancer"[tiab]) AND (2025/09/11:2026/09/11[dp])`	2026-09-11	pubmed

Data updated 20 days agoSource updated unknownsource: pubmed E-utilities

Literature

Linked publications (82)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedPublishedShowing 1–25 of 82 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
· N Engl J Med · 2019 · PMID 31157963 · validated civic_curation pubmed
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
· Lancet Oncol · 2020 · PMID 32416072 · validated civic_curation pubmed
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.
· Lancet Oncol · 2020 · PMID 32203698 · validated civic_curation pubmed
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study.